Skip to main content

Infigratinib Dosage

Medically reviewed by Last updated on Jun 19, 2023.

Applies to the following strengths: 100 mg-25 mg (125 mg daily-dose); 100 mg (100 mg daily-dose); 25 mg (75 mg daily-dose); 25 mg (50 mg daily-dose)

Usual Adult Dose for Cholangiocarcinoma of biliary tract

125 mg (one 100 mg capsule and one 25 mg capsule) orally once a day for 21 days on 7 days off of a 28-day cycle


Use: For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test

Renal Dose Adjustments

Liver Dose Adjustments

Dose Adjustments

Dose Reduction for Adverse Reactions:

Dose Modification for Adverse Reactions:
Retinal Pigment Epithelial Detachment (RPED):

If serum phosphate greater than 5.5 to 7.5 or less mg/dL:

Other Adverse Reactions:

Dosage Modification for Concomitant Use of Gastric Acid Reducing Agents:



Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

Storage requirements:


Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.